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Abstract Collagen is an important primary stimulus of platelets during the process of hemostasis. As with many other platelet s imuli, collagen signal 
transduction i volves the hydrolysis of inositol phospholipids; however, the mechanism which underlies th s event isnot well understood. Neither 
the collagen receptor nor the isoform of phospholipase C that is activated have been identified. We report hat collagen-activation of platelets induces 
tyrosine phosphorylation f phospholipase C-72 but not phospholipase C-71. We also show that the platelet low affinity Fc receptor (FcTRII), which 
mediates activation of platelets by immune complexes, and wheat germ agglutinin, which binds non-specifically toglycoprotein, stimulate phospho- 
lipase C-72 tyrosine phosphorylation. I  contrast, we could not detect phospholipase C-72 tyrosine phosphorylation in platelets stimulated by either 
thrombin or a stable thromboxane As analogue, U46619. 
Key words." Collagen; Fc7 receptor; Wheat germ agglutinin; Phospholipase C7; Human platelet 
1. Introduction 
During the initial stages of hemostasis, platelets are activated 
by adhesion to collagen in the connective tissue surrounding the 
site of injury. The activation of platelets by collagen, as with 
the majority of platelet stimuli, involves activation of phospho- 
inositide-specific phospholipase C (PLC) [1]. The mechanism 
of PLC activation by collagen has not been characterised, nor 
has the collagen receptor been identified. Several platelet sur- 
face proteins with collagen binding properties are candidate 
receptors (reviewed in reference [2]). These include: gpla/IIa 
(integrin ~z2fll), gplV (CD36), and two unidentified proteins, 
of 65 and 61 kDa. It is not yet certain which of these proteins 
is involved in collagen-stimulated activation of PLC. 
Platelets contain several PLC isozymes, including PLC-71, 
PLC-72, PLC-fl, PLC-8 and at least two unidentified cytosolic 
PLCs [3,4]. There is good evidence that PLC-fl is coupled via 
G-proteins, to receptors of several platelet agonists, including 
thrombin and thromboxane A2 (for review see [5]). Several 
platelet receptors however, do not have the seven transmem- 
brane domains typical of G-protein-linked receptors, yet have 
been shown to stimulate PLC and platelet activation; e.g. the 
platelet low-affinity antibody receptor (FcTRII) [6] which medi- 
ates activation of platelets by immune complexes. Since none 
of the putative collagen receptors have been found to have 
seven transmembrane domains, it is possible that the collagen 
receptor uses a mechanism of PLC activation similar to that of 
FcTRII. Indeed, there is evidence, based on the effects of tyro- 
sine kinase inhibitors, that both collagen and FcyRII  stimulate 
PLC through a mechanism involving tyrosine phosphorylation 
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[7,8]. These data suggest he involvement of PLC7 isozymes, 
which are regulated bytyrosine phosphorylation [9,10]. Indeed 
FcTRII induces tyrosine phosphorylation fPLC7 isoforms in 
two human monocytic ell lines, THP-1 [11] and U937 [12]. In 
contrast yrosine kinase inhibitors have little or no effect on 
PLC activation by thrombin or U46619, a thromboxane A2 
(TxA2) analogue [8]. Tyrosine phosphorylation f FcTRII dur- 
ing stimulation may be part of the mechanism of PLC activa- 
tion, since it occurs upstream of PKC activation and Ca 2+ 
mobilization [8]. Huang et al. [13] observed that the cytoplasmic 
tail of FcTRIIA, the form of FcTRII in platelets [14], contains 
a sequence motif closely related to a repeated tyrosine, leucine/ 
isoleucine motif, known as an antigen recognition activation 
motif (ARAM), which is responsible for coupling the T-cell 
receptor to the tyrosine kinase ZAP-70 (reviewed in [15]). Phos- 
phorylation of FcyRII  on tyrosine may also permit direct asso- 
ciation with PLC7 via SH2 interactions, as in the case of the 
receptors for, platelet-derived growth factor (PDGF-fl) and 
epidermal growth factor [16]. 
The evidence we present here suggests that collagen activates 
platelets through a mechanism similar to that used by FcTRII 
cross-linking. Both stimulation by collagen and FcTRII cross- 
linking, but neither thrombin or a stable TxA2 analogue, stim- 
ulate tyrosine phosphorylation f PLC-y2. 
2. Materials and methods 
2.1. Materials 
Monoclonal antibody (mAb) IV.3, specific for Fc7RII, was pur- 
chased from Madarex Inc., New Hampshire, USA. Anti-phosphoty- 
rosine mAb PY20 was purchased from ICN Flow (High Wycombe, 
Bucks., UK). Rabbit antiserum raised against residues 461 to 481, and 
1218 to 1239 of PLC-72 was prepared as described [17]. Rabbit antise- 
rum (06-152) raised against PLC-71, mAb (05-163) against PLC-T1 and 
anti-phosphotyrosine mAb 4G10 were purchased from UBI (New 
York, USA). Collagen (native collagen fibrils from equine tendons) was 
from Nycomed (Munich, Germany). Ro 31-8220 was a gift rom Roche 
Products (Welwyn Garden City, Herts., UK). BAPTA-AM was pur- 
chased from Calbiochem-Novabiochem (Nottingham, UK). Throm- 
bin, staurosporine, U46619, bovine serum albumin (fraction V) (BSA), 
Tween 20 and sheep F(ab')2 raised against mouse IgG (M-1522) were 
purchased from Sigma (Poole, Dorset, UK). Nonidet P-40 was pur- 
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chased from BDH (Poole, UK). ST271 was a gift from the Wellcome 
Foundation (Beckenham, UK). Horseradish peroxidase conjugated 
sheep anti-mouse IgG (NA931), donkey anti-rabbit IgG (NA934), and 
ECL reagents were from Amersham International (Cardiff, UK). 
PVDF western blotting membrane was from Bio-Rad (Hertfordshire, 
UK). All other reagents were of analytical grade. 
2.2. Platelet isolation and stimulation 
Twice washed human platelets were prepared from drug free volun- 
teers on the day of the experiment as previously described [7] and 
resuspended at a concentration f 8 x 108/ml in a modified Tyrode 
buffer consisting of NaC1 (134 mM), KCI (2.9 mM) Na2HPO4 (0.34 
mM), NaHCO3 (12 mM), HEPES (20 mM) MgC12 (1 raM), indometh- 
acin (10/aM) and EGTA (1 mM). All experiments were performed at 
37°C with continuous stirring (1200 rpm). FcyRII was stimulated by 
cross-linking with mAb IV.3 (1/ag/ml) and F(ab')2 anti-mouse IgG (30 
/ag/ml); mAb IV.3 was added 60 s before F(ab')2, the latter time being 
taken as the start of stimulation. Collagen was used at a concentration 
of 100/ag/ml added from a stock of 1 mg/ml. Stocks of protein kinase 
inhibitors taurosporine (1 mM), Ro 31-8220 (1 mM) and ST271 (10 
mM) were stored in Me2SO. Staurosporine and Ro 31-8220 were added 
60 s before agonist stimulation while ST271 was given 10 min before 
agonist addition. In experiments where platelets (8 x 10S/ml) were incu- 
bated with the intracellular Ca 2+ chelator BAPTA-AM (40/aM) the 
latter was added from a 10 mM stock in Me2SO, 15 min prior to agonist 
stimulation. Appropriate Me2SO controls were used. 
2.3. Immunoprecipitation and immunoblotting 
Following stimulation, platelets (8 x 108/ml) were lysed, either at 4 ° C 
for 30 min with an equal volume of ice-cold Nonidet P-40 extraction 
buffer [8] or radio-immunoprecipitation assay (RIPA) buffer, consist- 
ing of sodium deoxycholate (2% w/v), Triton X-100 (2% v/v), SDS 
(0.2%, w/v), NaCI (300 mM), Tris (20 mM), PMSF (1 mM), EDTA (10 
mM), Na3VO4 (2 mM) at pH 7.3; or at 190C with an equal volume of 
denaturing extraction buffer consisting of SDS (4% w/v), 2-mercap- 
toethanol (10% v/v), EDTA (10 raM), Tris (20 mM), PMSF (1 mM 
added from 100 mM in Me2SO), pH 7.3. In the latter case, samples were 
heated to 100°C then diluted 25-fold into Tris-buffered saline, Tris (20 
raM), NaC1 (137 mM) pH 7.6, containing Tween 20 (0.1% v/v) (TBS-T), 
BSA (2 mg/ml), PMSF (1 mM), prior to immunoprecipitation. Insolu- 
ble cell debris was removed by centrifugation either at 3,000 x g for 30 
min, for the denaturing protocol, or at 13,000 x g for 10 min, for the 
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Nonidet P-40 and RIPA protocol. The supernatant was precleared with 
20/al of protein A-Sepharose CL-4B which had been hydrated in TBS-T 
containing 10% (w/v) BSA and sodium azide (0.05% w/v). The superna- 
tant was incubated overnight with 5/al of antiserum to either PLC-y2, 
or PLC-71 and 20/al of protein A-Sepharose CL-4B. The protein 
A-Sepharose CL-4B pellet was washed using at least 6 sequential 20- 
fold dilutions, in TBS-T (4°C, containing PMSF (1 mM) and EDTA 
(1 mM). Immunopreeipitated protein was resolved by SDS-PAGE 
(10%) and Western blotted. The Western blot was probed initially with 
horseradish conjugated secondary antibody and ECL detection was 
used to identify bands of direct secondary antibody binding. The blot 
was then probed for phosphotyrosine using either mAb PY20 or mAb 
4G10, followed by reprobing with the secondary antibody and ECL 
detection. The blot was then stripped as described previously [7] and 
reprobed with either anti-PLC-yl monoclonal antibody and horse- 
radish peroxidase conjugated sheep anti-mouse IgG, or antiserum to 
PLC-y2 (1 : 200 dilution) and horseradish peroxidase conjugated don- 
key anti-rabbit IgG, followed by ECL detection. Each result was con- 
firmed in at least three independent experiments. 
3. Results 
3.1. Phosphorylation ofphospholipase C-y2 
Stimulation of platelets by both collagen, and by cross-link- 
ing Fc)'RII caused the tyrosine phosphorylation f PLC-)'2, as 
detected by immunoblotting of irnmunoprecipitated PLC-72 
with two different antiphosphotyrosine monoclonal antibodies 
(Figs. IA and 2). Fig. IA shows the tyrosine phosphorylation 
of PLC-)'2 immunoprecipitated under non-denaturing condi- 
tions from Nonidet P-40 lysed platelets, as detected mAb PY20. 
Fig. 2 shows the tyrosine phosphorylation of PLC-)'2 im- 
munoprecipitated from platelets lysed in 2% SDS, then diluted 
to permit immunoprecipitation, as detected using mAb 4G10. 
Equivalent amounts of PLC-)'2 were detectable in immunopre- 
cipitates from both unstimulated and stimulated samples (Fig. 
1A). We did not detect he presence of tyrosine phosphorylated 
protein specifically associated with immunoprecipitated PLC- 
7"2. 
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Fig. 1. Tyrosine phosphorylation f platelet PLC7 isozymes. (A) PLCy2 was immunoprecipitated from N nidet P-40 lysed unstimulated platelets 
(-), platelets stimulated for 120 s by cross-linking of FcTRII (Fc), as detailed in section 2, or platelets stimulated by collagen (100/ag/ml) for 120 s 
(C). The upper panel shows an anti-phosphotyrosine immunoblot using mAb PY20. The lower panel shows the appropriate s ction of the same blot 
after being stripped and reprobed for PLC72. Part B shows anti-phosphotyrosine (mAb PY20) immunoblots ofPLCy 1 immunoprecipitated (using 
anti-PLCy1 antiserum) from platelets (upper left hand panel) stimulated for 120 s with 100/ag/ml of collagen (C) or for 60 s by cross-linking ofFcTRII 
(Fc); and right hand upper panel, NIH3T3-F442A cells grown to confluence in 25 cm 2 flasks unstimulated (-) or stimulated for I0 min with 2 nM 
PDGF-fl (+), and lysed in ice-cold RIPA buffer. The lower two panels how the appropriate sections of the same blots after being stripped and 
reprobed for PLCT1 using a mAb against PLCyl. The position of the IgG heavy chain is marked on the upper panels. 
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Fig. 2. Time course ofPLCy2 tyrosine phosphorylation. The two panels 
show anti-phosphotyrosine immunoblots (mAb 4G10) of PLCy2 im- 
munoprecipitated from platelets lysed and boiled in 2% SDS, as de- 
scribed in section 2. The left hand panel shows the time course of 
PLCy2 tyrosine phosphorylation in response to FcyRII cross-linking. 
The right hand panel shows the time course of PLCy2 tyrosine phos- 
phorylation following the addition of 100/~g/ml collagen to the platelet 
suspension. The position of the IgG heavy chain s marked. 
Collagen and FcTRII stimulated tyrosine phosphorylation f 
PLC-y2 appears to occur on a time-scale similar to the onset 
of platelet functional responses, FcyRII  stimulated tyrosine 
phosphorylation f PLC-y2, detectable within 20 s and maxi- 
mal by 60 s (Fig. 2), correlated with phosphorylation of pleck- 
strin, the major protein kinase C (PKC) substrate in platelets 
(not shown). Similarly, collagen stimulated phosphorylation of 
both PLC-y2 and pleckstrin was first detectable 60 s after 
addition of collagen (Fig. 2 and not shown). 
Wheat germ agglutinin, which s ows binding specificity for 
glycoproteins containing sialic acid, N-acetylglucosamine, and 
N-acetylgalactosamine [18], including plb [19], also stimulated 
tyrosine phosphorylation f PLC-72 (Fig. 3). This is consistent 
with our unpublished observations that the potent non-selec- 
tive protein kinase inhibitor, staurosporine, inhibits wheat 
germ agglutinin stimulated formation of inositol phosphates, 
and the report by Yatomi et al. [20] that staurosporine inhibits 
wheat germ agglutin stimulated rise in cytosolic Ca 2÷ concen- 
tration. The protein tyrosine phosphatase inhibitor, peroxova- 
nadate, which stimulates inositol phosphate production n 
platelets [7], also stimulated strong tyrosine phosphorylation f 
PLC-y2 (not shown). 
We were unable to detect yrosine phosphorylation of PLC- 
y2 stimulated by a stable thromboxane A2 analogue, U46619 
(20 pM) or thrombin (1 unit/ml), over stimulation periods be- 
tween 10 and 120 s (Fig. 3). This differs from a previous tudy 
[21] which reports transient thrombin-stimulated yrosine phos- 
phorylation of PLC-y2, peaking at 60 s of stimulation. We 
tested whether the presence of indomethacin and EGTA in our 
platelet suspension i hibits this response, but were still unable 
to detect PLC-y2 tyrosine phosphorylation with either mAb 
PY20 or mAb 4G10 (not shown). 
3.2. Phosphorylation of  phospholipase C-71 
In contrast o the results obtained for PLC-y2, and our 
previous tudy of peroxovanadate stimulated platelets [7], we 
have been unable to detect yrosine phosphorylation f PLC-y 1 
in platelets timulated by collagen, FcyRII  cross-linking (Fig. 
1B) or thrombin (not shown). A positive control of PLC-z1 
tyrosine phosphorylation i PDGF-fl stimulated NIH3T3- 
F442A cells is shown in Fig. 1C. Others have also been u able 
to detect thrombin stimulated tyrosine phosphorylation of 
PLC-yl in platelets [22,23]. In contrast, Guinebault et al. [24] 
detected PLC-yl in protein from thrombin stimulated, dig- 
itonin-lysed platelets, purified on agarose-conjugated an- 
tiphosphotyrosine antibody. However, this procedure does not 
distinguish between tyrosine phosphorylation of PLC-y1 and 
its association with tyrosine phosphorylated protein. In plate- 
lets, PLC-y1 associates with the GTPase activating protein of 
p21 ras (rasGAP), which is phosphorylated on tyrosine in re- 
sponse to thrombin stimulation [23]. Similarly, PLC-y1 associ- 
ates with various growth factor receptors in fibroblast cell lines 
[16,25], as well as several uncharacterised tyrosine phosphor- 
ylated proteins (the most notable being pp35/36) in T- and 
B-lymphocytes and related cell-lines [26,27]. 
3.3. Effect of intracellular Ca e+ chelation and protein kinase C 
inhibition on PLC-y2 phosphorylation 
We have previously used the combination of the selective 
PKC inhibitor, Ro 31-8220, and the intra-cellular Ca 2÷ chela- 
tor, BAPTA-AM, to demonstrate hat the tyrosine phosphoryl- 
ation of FcyRII  occurs independently of PKC activation and 
Ca 2+ mobilization [8]. Similarly, PLC-y2 is tyrosine phos- 
phorylated in platelets pre-incubated with Ro 31-8220 and 
BAPTA-AM, prior to stimulation by collagen or FcyRII  cross- 
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Fig. 3. Protein kinase C inhibition and intracellular Ca 2÷ chelation, and 
the effect of other platelet agonists on PLCy2 tyrosine phosphoryla- 
tion. All three panels show antiphosphotyrosine immunoblots (com- 
bined mAb PY20 and 4G10) of PLCy2 immunoprecipitated from SDS 
lysed platelets. Part A shows the tyrosine phosphorylation f PLCy2 
from platelets which had been pre-incubated as indicated, with Ro 
31-8220 and BAPTA-AM, as described in section 2, and stimulated for 
120 s, either by cross-linking FcyRII (Fc) or by the addition of 100 
/zg,/ml of collagen (C). Part B (i) shows the effect of thrombin (1 unit/ml) 
stimulation of platelets over 30, 60 and 120 s, on PLCy2 tyrosine 
phosphorylation, as compared to unstimulated platelets (-) and colla- 
gen stimulated (120 s, 100/zg/ml) p atelets (C). Part B (ii) shows the 
effect of wheat germ agglutinin (WGA; 60 s, 100/zg/ml) and U46619 
(U4; 60 s, 20/zM) stimulation as compared to unstimulated platelets 
(-) and platelets stimulated for 120 s with 100 pg/ml of collagen (C). 
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linking (Fig. 3A). This is consistent with tyrosine phosphoryla- 
tion of PLC-y2 being upstream of second-messenger formation 
and responses such as aggregation which regulate tyrosine 
phosphorylation f several platelet proteins. 
4. Discussion 
Our studies show that stimulation of platelets by collagen, 
FcyRII cross-linking and wheat germ agglutinin, causes tyro- 
sine phosphorylation f PLC-y2 but not PLC-yl. These obser- 
vations offer a molecular explanation as to why these platelet 
stimuli are particularly sensitive to tyrosine kinase inhibitors 
[7,8,20]. It remains to be shown whether platelet PLC-~'2 is 
indeed activated by tyrosine phosphorylation, but there is suf- 
ficient precedent from the studies of PLC-71, and circumstan- 
tial evidence from the effect of tyrosine kinase inhibitors, to
speculate that it is. Moreover, when Rat-2 cells overexpressing 
PLC-y2 were treated with PDGF, an increase in both the tyro- 
sine phosphorylation and the in vivo activity of PLC-y2 was 
observed [28]. Also, the time course of anti-IgM stimulated 
PLC-y2 tyrosine phosphorylation in WEHI-231 B-cells corre- 
lates well with the production of inositol phosphates [29]. 
There are contrasting reports with regard to the level of 
PLC-y isoforms in platelets. Torti and Lapetina [23] suggest 
that PLC-yl accounts for approximately 62% of the total 
phosphatidylinositol (4,5)-bisphosphate (PIP2) hydrolysing ac- 
tivity in unstimulated platelets. This estimate contrasts with the 
results of Banno et al. [4], which show that the platelet Fast 
Q-Sepharose fraction containing both PLC-yl and PLC-y2, 
accounts for no more than 6% of the total cytosolic PIP2 
hydrolysing activity. Consistent with this, depletion of 40 to 
50% of platelet PLC-72 by immunoprecipitation, does not 
cause significant reduction in PIP2 hydrolysing activity of 
platelet lysate [21]. Our results are consistent with tyrosine 
phosphorylation f PLC-72, but not PLC-yl, playing a signif- 
icant role in collagen and FcyRII-stimulation of platelets. This 
is analogous to anti-IgM stimulated B-cell lines in which both 
expression [30] and tyrosine phosphorylation [29] of PLC-72 is 
predominant over PLC-yl. 
Our findings prompt he question, which tyrosine kinase is 
responsible for the phosphorylation f PLC-y2? This is not a 
trivial matter to resolve, especially in the case of collagen and 
wheat germ agglutinin stimulation because of the uncertainty 
of the receptor involved. More information, from studies in 
platelets and other-cell types, is available on FcyRII signal 
transduction. FcyRII co-immunoprecipitates with several src 
family tyrosine kinases: pp59 fy~ in human tonsil B-cells [31], 
pp59 hck and pp56 lyn in THP-1 cells [32] and pp58 fg~ in neutro- 
phils [33]. Huang et al. [13] examined the role of the src-like 
kinases, in platelet FcTRII signal transduction. The only mem- 
ber of this family which had a detectable increase in auto- 
phosphorylating activity was pp6& re, 2 to 10 min after FcyRII 
stimulation, but the change was small. They were unable to 
detect association of any of the src-like kinases with FcTRII. 
Studies in the human monocytic ell lines THP-1 [11] and 
HL60 [34] have implicated the ZAP-70-homologous tyrosine 
kinase pp72 syk in FcyRII signalling. In HL60 cells, pp72 syk is 
phosphorylated on tyrosine in response to Fc~,RII cross-link- 
ing. In THP-1 cells, pp72 ~yk associates with FcyRII, is 
phosphorylated on tyrosine and has increased in vitro auto- 
phosphorylating activity following FcyRII stimulation. Simi- 
larly in platelets, FcTRII cross-linking induces tyrosine phos- 
phorylation of a 70 kDa protein upstream of second-messen- 
gers [8]; this protein has been identified (Blake, Poole, Asselin, 
Schieven and Watson, unpublished r sults) as pp72 syk. We have 
also been able to detect an uncharacterised tyrosine ki ase 
activity associated with Fc~,RII from platelets timulated by 
FcTRII cross-linking or peroxovanadate, by subjecting Fc~,RII 
immunoprecipitates o in vitro kinase assay and observing the 
phosphorylation of Fc~'RII on tyrosine, as determined by 
phosphoaminoacid analysis (Blake, Poole, Asselin, Schieven 
and Watson, unpublished results). Interestingly, activation of 
porcine platelets by wheat germ agglutinin stimulates the activ- 
ity of pp72 syk [35], and both collagen and wheat germ agglutinin 
activation of human platelets timulates tyrosine phosphoryla- 
tion of pp72 syk (Blake, Poole, Asselin, Schieven and Watson, 
unpublished results). These results lead us to speculate that 
pp72 Syk participates in the mechanism of PLC-72 tyrosine phos- 
phorylation and activation in platelets timulated by collagen, 
Fc~'RII cross-linking, and wheat germ agglutinin. This model 
would predict that the collagen receptor, like FcyRII, has an 
ARAM-like motif which, when phosphorylated, binds pp72 syk. 
However, pp72 sykis also activated in porcine platelets timu- 
lated by the thromboxane analogue U44069 [36], and by throm- 
bin in a cell-free system [37]; yet these stimuli do not induce 
tyrosine phosphorylation of PLC-72. It is possible that 
phosphorylated pp72 ~yk must have the appropriate sub-cellular 
localization in order to induce tyrosine phosphorylation of 
PLC-72. 
We have failed to confirm previous observations [21] of 
thrombin-stimulated PLC-~'2 tyrosine phosphorylation. The 
reason for this discrepancy is not clear as we were careful to 
reproduce the conditions used in the original study. To our 
knowledge there has only been one other report of tyrosine 
phosphorylation f PLC-7 isoforms in response to activation 
of a G-protein coupled receptors. Gusovsky et al. [38] demon- 
strated that the m5 muscarinic receptor transfected into Chi- 
nese hamster ovary cells induced tyrosine phosphorylation f
PLC-yI, but in a manner dependent upon the entry of extracel- 
lular Ca 2÷, suggesting that this is not a direct receptor-linked 
event; a result which is consistent with our findings. 
In summary, we have demonstrated that a subset of platelet 
stimuli, which include adhesion to fibrilar collagen and cross- 
linking of FcyRII, induce the tyrosine phosphorylation of 
PLC-y2, but not PLC-yl. We suggest hat this is part of a 
mechanism responsible for stimulating phosphoinositide hy- 
drolysis and subsequent downstream responses, by non-G-pro- 
tein-coupled receptors in platelets. Our comparison of the 
mechanisms of collagen and Fc~zRII stimulation lead us to 
speculate that the collagen receptor will prove to be a glycopro- 
rein which is phosphorylated on tyrosine in response to colla- 
gen stimulation. 
Acknowledgements: S.P.W. is a Royal Society University Research Fel- 
low; R.A.B. is in receipt of a British Heart Foundation Studentship. 
This work was supported by the Wellcome Trust. 
References 
[1] Watson, S.P., Reep, B., McConnell, R.T. and Lapetina, E.G. 
0985) Biochem. J. 226, 831-837. 
[2] Santoro, S.A. 0988) in: Platelet Membrane Receptors: Molecular 
Biology, Immunology, Biochemistry and Pathology (Jamieson, 
G.A., Ed.) pp. 291-314, Liss, New York. 
216 1LA. Blake et al./FEBS Letters 353 (1994) 212-216 
[3] Banno, Y., Yu, A., Nakashima, T., Homma, Y., Takenawa, T. and 
Nozawa, Y. (1990) Biochem. Biophys. Res. Commun. 167, 396- 
401. 
[4] Banno, Y., Nakashima, T., Kumada, T., Ebisawa, K., Nonomura, 
Y. and Nozawa, Y. (1992) J. Biol. Chem. 267, 6488-6494. 
[5] Brass, L.F., Hoxie, J.A. and Manning, D.R. (1993) Thromb. 
Haemost. 70, 217-223. 
[6] Anderson, G.P. and Anderson, C.L. (1990) Blood 76, 1165-1172. 
[7] Blake, R.A., Walker, T.R. and Watson, S.P. (1993) Biochem. J. 
290, 471-475. 
[8] Blake, R.A., Asselin, J., Walker, T.R. and Watson, S.P. (1994) 
FEBS Lett. 342, 15-18. 
[9] Nishibe, S., Wahl, M.I., Hernandez-Sotomayor, S.M., Tonks, 
N.K., Rhee, S.G. and Carpenter, G. (1990) Science 250, 1253- 
1256. 
[10] Goldschmidt-Clermont, P.J. Kim, J.W., Machesky, L.M., Rhee, 
S.G. and Pollard, T.D. (1991) Science 251, 1231-1233. 
[11] Kiener, P.A., Rankin, B.M., Burkhardt, A.L., Schieven, G.L., 
Gilliland, L.K., Rowley, R.B., Bolen, J.B. and Ledbetter, J.A. 
(1993) J. Biol. Chem. 268, 24442-24448. 
[12] Liao, F., Shin, H.S. and Rhee, S.G. (1992) Proc. Natl. Acad. Sci. 
USA 89, 3659-3663. 
[13] Huang, M.M., Indik, Z., Brass, L.F., Hoxie, J.A., Schreiber, A.D. 
and Brugge, J.S. (1992) J. Biol. Chem. 267, 5467-5473. 
[14] Cassel, D.L., Keller, M.A., Surrey, S., Schwartz, E., Schreiber, 
A.D., Rappaport, E.F. and McKenzie, S.E. (1993) Mol. Immunol. 
30, 451-460. 
[15] Weiss, A. (1993) Cell 73, 209-212. 
[16] Anderson, D., Koch, C.A., Grey, L., Ellis, C., Moran, M.F. and 
Pawson, T. (1990) Science 250, 979-982. 
[17] Deans, J.P., Schieven, G.L., Shu, G.L., Valentine, M.A., Gilliland, 
L.A., Aruffo, A., Clark, E.A. and Ledbetter, J.A. (1993) J. Immu- 
nol. 151, 4494-4504. 
[18] Ganguly, P. and Fossett, N.G. (1984) Blood 63, 181-187. 
[19] Moroi, M. and Jung, S.M. (1984) Biochim. Biophys. Acta 798, 
295-301. 
[20] Yatomi, Y., Ozaki, Y., Koike, Y., Satoh, K. and Kume, S. (1993) 
Biochem. Biophys. Res. Commun. 191,453-458. 
[21] Tate, B.F. and Rittenhouse, S.E. (1993) Biochim. Biophys. Acta 
1178, 281-285. 
[22] Nozawa, Y., Banno, Y. and Nagata, K. (1993) Adv. Exp. Med. 
Biol. 344, 37-47. 
[23] Torti, M. and Lapetina, E.G. (1992) Proc. Natl. Acad. Sci. USA 
89, 7796-7800. 
[24] Guinebault, C., Payrastre, B., Sultan, C., Mauco, G., Breton, M., 
Levy-Toledano, S., Plantavid, M. and Chap, H. (1993) Biochem. 
J. 292, 851-856. 
[25] Mohammadi, M., Honegger, A.M., Rotin, D., Fischer, R., Bellot, 
F., Li, W., Dionne, C.A., Jaye, M., Rubinstein, M. and Schlessin- 
ger, J. (1991) Mol. Cell Biol. 11, 5068-5078. 
[26] Weber, J.R., Bell, G.M., Han, M.Y., Pawson, T. and Imboden, 
J.B. (1992) J. Exp. Med. 176, 373-379. 
[27] Gilliland, L.K., Schieven, G.L., Norris, N.A., Kanner, S.B., 
Aruffo, A. and Ledbetter, J.A. (1992) J. Biol. Chem. 267, 13610- 
13616. 
[28] Sultzman, L., Ellis, C., Lin, L.L., Pawson, T. and Knopf, J. (1991) 
Mol. Cell Biol. 11, 2018-2025. 
[29] Hempel, W.M., Schatzman, R.C. and DeFranco, A.L. (1992) 
J. Immunol. 148, 3021-3027. 
[30] Coggeshall, K.M., McHugh, J.C. and Altman, A. (1992) Proc. 
Natl. Acad. Sci. USA 89, 5660-5664. 
[31] Sarmay, G., Pecht, I. and Gergely, J. (1994) Proc. Natl. Acad. Sci. 
USA 91, 4140-4144. 
[32] Ghazizadeh, S., Bolen, J.B. and Fleit, H.B. (1994) J. Biol. Chem. 
269, 8878-8884. 
[33] Hamada, F., Aoki, M., Akiyama, T. and Toyoshima, K. (1993) 
Immunology 90, 6305-6309. 
[34] Argawal, A., Salem, P. and Robbins, K.C. (1993) J. Biol. Chem. 
268, 15900-15905. 
[35] Ohta, S., Taniguchi, T., Asahi, M., Kato, Y., Nakagawara, G. and 
Yamamura, H. (1992) Biochem. Biophys. Res. Commun. 185, 
1128-1132. 
[36] Maeda, H., Taniguchi, T., Inazu, T., Yang, C., Nakagawara, G. 
and Yamamura, H. (1993) Biochem. Biophys. Res. Commun. 197, 
62-67. 
[37] Sada, K., Yanagi, S. and Yamamura, H. (1994) Biochem. Biophys. 
Res. Commun. 200, 1-7. 
[38] Gusovsky, F., Lueders, J.E., Kohn, E.C. and Felder, C.C. (1993) 
J. Biol. Chem. 268, 7768-7772. 
